Veeva Systems Inc. (NYSE:VEEV) Stock Has Consensus Target Price of $284.88 According to Analysts

Shares of Veeva Systems Inc. (NYSE:VEEV) have been assigned an average rating of “Moderate Buy” from the twenty-eight ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $284.88.

VEEV has been the topic of several research reports. UBS Group upped their target price on Veeva Systems from $190.00 to $290.00 and gave the stock a “neutral” rating in a research report on Thursday, August 27th. Wall Street Zen cut Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Oppenheimer boosted their price objective on Veeva Systems from $225.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, August 17th. Stifel Nicolaus set a $300.00 price objective on shares of Veeva Systems in a research report on Thursday, August 27th. Finally, Robert W. Baird upped their price target on Veeva Systems from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th.

Veeva Systems News Summary

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Wall Street analysts reportedly see approximately 30% potential upside for Veeva, supporting the bullish case for the stock despite its recent weakness. Why Analysts See 30% Upside Ahead Analysts See Potential Rally
• Positive Sentiment: Veeva’s role as software infrastructure for pharmaceutical and biotechnology companies positions it to benefit from the use of artificial intelligence in medicine, including research, regulatory and commercial workflows. AI Will Revolutionize Medicine
• Positive Sentiment: Servier adopted Veeva OpenData globally to scale its AI initiatives, providing evidence of enterprise adoption and potential support for Veeva’s data and AI-related growth. Servier Adopts Veeva OpenData Globally
• Positive Sentiment: ACTO achieved Veeva Gold Product Partner status, potentially strengthening Veeva’s partner ecosystem and implementation capabilities. ACTO Achieved Veeva Gold Product Partner Status
• Neutral Sentiment: Commentary highlighting Veeva among software stocks that rebounded during the third quarter reinforces investor interest, but does not identify a new company-specific catalyst. Software Stocks and AI Commentary
• Negative Sentiment: Veeva declined while the overall market gained. The coverage offers no fresh earnings warning or negative operating update, so the move may reflect profit-taking and elevated valuation sensitivity after a strong run. Veeva Stock Sinks as Market Gains

Veeva Systems Price Performance

NYSE:VEEV opened at $273.22 on Wednesday. The firm has a market cap of $44.24 billion, a PE ratio of 44.94, a P/E/G ratio of 1.20 and a beta of 0.93. Veeva Systems has a 1-year low of $148.05 and a 1-year high of $310.50. The firm has a 50 day simple moving average of $252.60 and a 200-day simple moving average of $200.06.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The firm had revenue of $927.96 million during the quarter, compared to analyst estimates of $905.38 million. During the same quarter in the prior year, the business posted $1.99 earnings per share. Veeva Systems’s revenue for the quarter was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, sell-side analysts expect that Veeva Systems will post 6.7 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total value of $195,780.00. Following the transaction, the director owned 3,242 shares in the company, valued at $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas Schwenger sold 36,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the sale, the insider owned 19,449 shares of the company’s stock, valued at approximately $4,866,723.27. This trade represents a 64.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 46,750 shares of company stock valued at $12,017,360 over the last quarter. Corporate insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Veeva Systems

Large investors have recently added to or reduced their stakes in the stock. SHP Wealth Management bought a new stake in Veeva Systems in the 4th quarter valued at $26,000. Compass Financial Management LLC purchased a new position in Veeva Systems during the second quarter valued at approximately $27,000. Burkett Financial Services LLC purchased a new position in shares of Veeva Systems in the 3rd quarter valued at $27,000. Arlington Trust Co LLC bought a new stake in Veeva Systems during the second quarter valued at about $29,000. Finally, Field & Main Bank bought a new position in Veeva Systems in the second quarter worth about $29,000. Institutional investors own 88.20% of the company’s stock.

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.